This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

Safety Worries Over Celgene's Experimental Crohn's Drug Overblown

  • Tickers in this article:
  • CELG

The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.

09/17/14 - 08:26 AM EDT

SEC Slaps Biotech Hedge Fund for Short-Selling Violations

On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.

09/16/14 - 01:04 PM EDT

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.

09/16/14 - 09:48 AM EDT

SEC Slaps Biotech Hedge Fund for Short-Selling Violations

SEC Slaps Biotech Hedge Fund for Short-Selling Violations

On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.

09/16/14 - 01:04 PM EDT

Cognizant Buys TriZetto for $2.7B, Seizing Opportunity for Growth

  • Tickers in this article:
  • CTSH

Cognizant Technology Solutions said it would buy private health care IT services company TriZetto for $2.7 billion in cash.

09/15/14 - 12:05 PM EDT

Gilead Expands Access of Hepatitis C Drug in Developing Countries

  • Tickers in this article:
  • GILD
  • MYL

Gilead said it will license its hepatitis C drug Sovaldi to seven drugmakers in India to expand access to the medicine in developing countries.

09/15/14 - 01:38 PM EDT

NPS Pharma Hormone Drug Wins Shaky Endorsement From FDA Panel

NPS Pharma Hormone Drug Wins Shaky Endorsement From FDA Panel

  • Tickers in this article:
  • NPSP

NPS Pharmaceuticals shares are weak Monday following a rough outing for its hormone replacement therapy Natpara at an FDA advisory panel on Friday.

09/15/14 - 09:32 AM EDT

Avanir's Over-Priced Cough Syrup Touted for Role in Alzheimer's Agitation

Avanir's Over-Priced Cough Syrup Touted for Role in Alzheimer's Agitation

  • Tickers in this article:
  • AVNR

Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow high

09/15/14 - 10:19 AM EDT

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

Ebola-Stricken Doc Receives Experimental Drug, But Which One?

Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.

09/11/14 - 02:20 PM EDT

Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal

Third Time Was No Charm, FDA Denies Amarin Vascepa SPA Appeal

  • Tickers in this article:
  • AMRN

Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.

09/12/14 - 09:43 AM EDT

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.

09/11/14 - 01:23 PM EDT

Marathon Oil, Amgen Smart Long Haul Stocks Says Forester Fund Manager

Marathon Oil is a restructuring story and is cheap compared to fellow North American E&P players, said Thomas Forester, portfolio manager for the Forester Value Fund.

09/10/14 - 06:20 PM EDT

Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs

Trading Guidelines for Amgen, Biogen Idec, Gilead, 3 Other Biotechs

Here are some numbers that may help you navigate the volatile and expensive biotech sector.

09/11/14 - 10:02 AM EDT

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

Trade Ebola Stocks? Sure, But Don't Bet on Big Business Opportunity

The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)

09/10/14 - 09:36 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,254.47 +97.62 0.57%
S&P 500 2,009.53 +7.96 0.40%
NASDAQ 4,589.5430 +27.3540 0.60%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs